Protagonist Therapeutics, Inc
PTGX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$138.43
KIRA · Stoqly’s AI analyst, in plain words
- Protagonist Therapeutics, Inc had $46.0M of revenue in fiscal 2025, down 89.4% on the year before. Over five years, revenue changed +10.0% a year on average.
- Its operating margin was −343.6%, down 401.8 pts: of every 100 in sales, about −344 is left after running the business.
- Protagonist Therapeutics, Inc lost $130M in fiscal 2025.
- Free cash flow was $56.1M in fiscal 2025, 121.9% of revenue.
Market cap
$9.8B
P/E
134.4x
Revenue
$46.0M
Net income
−$130M
Free cash flow
$56.1M
Operating margin
−343.6%
Protagonist Therapeutics, Inc in 30 seconds · fiscal 2025
Are sales growing?
−89.4%
No. Sales fell 89.4% last year.
Does it make a profit?
−282.8%
No. It lost money last year.
Does profit turn into cash?
121.9%
Yes. 121.9% of sales ends up as free cash.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
134.4x
One share costs 134.4 times its yearly profit per share.
What Protagonist Therapeutics, Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Protagonist Therapeutics, Inc
- CIK
- 0001377121
Protagonist Therapeutics, Inc · PTGX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $27.4M | $26.6M | $60.0M | $434M | $46.0M |
| Revenue growth | −4.4% | −2.8% | 125.7% | 624.1% | −89.4% |
| Operating margin | −460.0% | −494.2% | −156.1% | 58.2% | −343.6% |
| Net income | −$126M | −$127M | −$79.0M | $275M | −$130M |
| Net margin | −458.9% | −479.3% | −131.6% | 63.3% | −282.8% |
| Diluted EPS | −$2.71 | −$2.60 | −$1.39 | $4.23 | −$2.05 |
| Cash | |||||
| Cash from operations | −$108M | −$108M | −$70.2M | $184M | $57.7M |
| Capital expenditure | $1.1M | $0.8M | $0.6M | $1.4M | $1.6M |
| Free cash flow | −$109M | −$109M | −$70.8M | $183M | $56.1M |
| FCF margin | −398.3% | −409.8% | −118.1% | 42.1% | 121.9% |
| Share count change | 34.7% | 5.9% | 15.7% | 14.6% | −2.3% |
| Debt and strength | |||||
| Cash and short-term investments | $327M | $237M | $342M | $419M | $567M |
| Shareholders' equity | $300M | $216M | $337M | $675M | $615M |
| Current ratio | 7.7x | 7.8x | 16.7x | 12.5x | 12.7x |
| Returns and quality | |||||
| Return on equity | −43.3% | −49.4% | −28.6% | 54.4% | −20.2% |
| Return on tangible equity | −41.8% | −59.1% | −23.5% | 40.8% | −21.2% |
| Piotroski F-score | 1 | 3 | 4 | 4 | 4 |
| Altman Z'' | 5.9 | 2.0 | 15.4 | 15.8 | 13.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$87.7M
7 insiders
Of sales under plans
51%
$44.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Protagonist Therapeutics, Inc · PTGX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $138.43 a share, the company is worth $9.8B: 134.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001377121). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.